129.46 USD
+0.18 (+0.14%)
129.5 USD
+0.04 (+0.03%)
Taking everything into account, BPMC scores 4 out of 10 in our fundamental rating. BPMC was compared to 535 industry peers in the Biotechnology industry. Both the profitability and financial health of BPMC have multiple concerns. BPMC is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year BPMC has reported negative net income.
BPMC had a negative operating cash flow in the past year.
BPMC had negative earnings in 4 of the past 5 years.
BPMC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
BPMC has a Return On Assets of -13.03%. This is amongst the best in the industry. BPMC outperforms 82.55% of its industry peers.
BPMC's Return On Equity of -45.52% is fine compared to the rest of the industry. BPMC outperforms 67.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.03% | ||
| ROE | -45.52% | ||
| ROIC | N/A |
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 96.48%, BPMC belongs to the best of the industry, outperforming 96.22% of the companies in the same industry.
BPMC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
BPMC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BPMC has more shares outstanding
Compared to 1 year ago, BPMC has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.51 indicates that BPMC is not in any danger for bankruptcy at the moment.
BPMC has a Altman-Z score of 3.51. This is in the better half of the industry: BPMC outperforms 74.10% of its industry peers.
BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BPMC (1.01) is worse than 76.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.51 |
ROIC/WACCN/A
WACC10.27%
2.3 Liquidity
A Current Ratio of 2.80 indicates that BPMC has no problem at all paying its short term obligations.
BPMC has a Current ratio of 2.80. This is in the lower half of the industry: BPMC underperforms 66.73% of its industry peers.
BPMC has a Quick Ratio of 2.75. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
BPMC has a Quick ratio of 2.75. This is in the lower half of the industry: BPMC underperforms 65.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
BPMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.24%, which is quite impressive.
Looking at the last year, BPMC shows a very strong growth in Revenue. The Revenue has grown by 99.14%.
The Revenue has been growing by 50.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
3.2 Future
BPMC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.63% yearly.
Based on estimates for the next years, BPMC will show a very strong growth in Revenue. The Revenue will grow by 26.27% on average per year.
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 131.18, the valuation of BPMC can be described as expensive.
Based on the Price/Forward Earnings ratio, BPMC is valued cheaply inside the industry as 87.77% of the companies are valued more expensively.
BPMC is valuated expensively when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 131.18 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BPMC's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as BPMC's earnings are expected to grow with 46.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.32%
EPS Next 3Y46.02%
5. Dividend
5.1 Amount
BPMC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
129.46
+0.18 (+0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.31%
Inst Owner Change-97.58%
Ins Owners0.84%
Ins Owner Change-178.88%
Market Cap8.37B
Revenue(TTM)562.12M
Net Income(TTM)-155.73M
Analysts68
Price Target132.96 (2.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.05%
Min EPS beat(2)-38.05%
Max EPS beat(2)-10.05%
EPS beat(4)2
Avg EPS beat(4)0.22%
Min EPS beat(4)-38.05%
Max EPS beat(4)39.24%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)9
Avg EPS beat(12)6.42%
EPS beat(16)11
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-5.77%
Max Revenue beat(2)-1.61%
Revenue beat(4)1
Avg Revenue beat(4)5.58%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)30.77%
Revenue beat(8)5
Avg Revenue beat(8)10.01%
Revenue beat(12)8
Avg Revenue beat(12)15.3%
Revenue beat(16)11
Avg Revenue beat(16)15.01%
PT rev (1m)0.02%
PT rev (3m)3.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.4%
EPS NY rev (1m)0%
EPS NY rev (3m)23.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 131.18 | ||
| P/S | 14.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 24.47 | ||
| P/tB | 24.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.22
EYN/A
EPS(NY)0.99
Fwd EY0.76%
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS8.69
BVpS5.29
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.03% | ||
| ROE | -45.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.48% | ||
| FCFM | N/A |
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 33.61% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 3.51 |
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.02%
EBIT Next 3Y49.05%
EBIT Next 5Y35.74%
FCF growth 1Y69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.45%
OCF growth 3YN/A
OCF growth 5YN/A
BLUEPRINT MEDICINES CORP / BPMC FAQ
Can you provide the ChartMill fundamental rating for BLUEPRINT MEDICINES CORP?
ChartMill assigns a fundamental rating of 4 / 10 to BPMC.
What is the valuation status of BLUEPRINT MEDICINES CORP (BPMC) stock?
ChartMill assigns a valuation rating of 2 / 10 to BLUEPRINT MEDICINES CORP (BPMC). This can be considered as Overvalued.
Can you provide the profitability details for BLUEPRINT MEDICINES CORP?
BLUEPRINT MEDICINES CORP (BPMC) has a profitability rating of 3 / 10.
How financially healthy is BLUEPRINT MEDICINES CORP?
The financial health rating of BLUEPRINT MEDICINES CORP (BPMC) is 3 / 10.
What is the earnings growth outlook for BLUEPRINT MEDICINES CORP?
The Earnings per Share (EPS) of BLUEPRINT MEDICINES CORP (BPMC) is expected to grow by 76.13% in the next year.